Team Konexio

  • NSE Warns Investors Against Illegal ‘Dabba Trading’ Platform

    NSE Warns Investors Against Illegal ‘Dabba Trading’ Platform

    Mumbai : It has been brought to the notice of the National Stock Exchange of India Limited (NSEIL/ Exchange) that a person named “Ankit” operating through mobile number “7310892297”, Facebook page named “DABBA TRADING INDIA”…

  • NSE Warns Against ‘Profit Trading’ Scam Seeking Login Credentials

    NSE Warns Against ‘Profit Trading’ Scam Seeking Login Credentials

    Mumbai: It has been brought to the notice of the National Stock Exchange of India Ltd. (NSE/Exchange) that a person named “Krishna” claiming to be associated with an entity named “Profit Trading”, operating through mobile…

  • LIC’s 70th Anniversary: 7 Decades of Trust, Growth & Leadership

    LIC’s 70th Anniversary: 7 Decades of Trust, Growth & Leadership

    The Life Insurance Corporation of India (LIC), the country’s leading life insurer and a financial institution of national significance, is proudly celebrating its 70th Anniversary on 1st September 2026. From its establishment on 1st September,…

  • ESDS IPO Sees Strong Demand – Subscribed 24.49x on Day 2

    ESDS IPO Sees Strong Demand – Subscribed 24.49x on Day 2

    Mumbai: The Initial Public Offering of ESDS Software Solution Limited was subscribed 24.49 times on the second day of bidding, demonstrating strong demand from retail and non-institutional investors for this IPO. The issue received bids…

  • India’s Q1 GDP Growth Hits 7.8%: Resilience Amid Challenges

    India’s Q1 GDP Growth Hits 7.8%: Resilience Amid Challenges

    India’s Q1 FY2026–27 GDP data is broadly positive but warrants cautious interpretation. Real GDP growth accelerated to 7.8% from 6.9% a year earlier, while nominal GDP growth rose to 10.3% from 8.1%. Real GVA growth…

  • Zydus’s Saroglitazar Hits Primary Endpoint in MASH Phase 2b Trial

    Zydus’s Saroglitazar Hits Primary Endpoint in MASH Phase 2b Trial

    Ahmedabad, India:Zydus, a leading innovation-led global lifesciences company, today announced positive topline results from its completed EVIDENCES-X™ Phase II(b), prospective, multicentre, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of Saroglitazar Magnesium in…